SCHEMBL8239704

SCHEMBL8239704

Cc1cnc2[nH]c(N)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP6 P51161 1/20 0.44
NOS3 P29474 2/20 0.41
NOS2 P35228 2/20 0.41
NOS1 P29475 1/20 0.41
ABL1 P00519 1/20 0.41
RET P07949 1/20 0.41
KDR P35968 1/20 0.41
CDK7 P50613 1/20 0.41
CDK5 Q00535 1/20 0.41
PRKAA1 Q13131 1/20 0.41
AURKB Q96GD4 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
TYMS P04818 4/20 0.37
CYP1A2 P05177 1/20 0.37
CCR1 P32246 1/20 0.36
CCR5 P51681 1/20 0.36
CCR8 P51685 1/20 0.36
ALDH1A1 P00352 2/20 0.34
MASP2 O00187 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7916579 0.80 CDK5 (0.42) NOS3NOS2NOS1ABL1RET
SCHEMBL14690389 0.77 ALDH1A1 (0.46) FABP6ABL1RETKDRCDK7
SCHEMBL14689970 0.77 HTR3E (0.50) FABP6TYMSALDH1A1MASP2MEN1
SCHEMBL1715982 0.77 CACNA1H (0.38) NOS3NOS2NOS1ABL1RET
SCHEMBL12829701 0.77 FABP6 (0.37) FABP6ABL1RETKDRCDK7
SCHEMBL24278167 0.77 HRH4 (0.39) FABP6ABL1RETKDRCDK7
SCHEMBL13631452 0.77 TYMS (0.41) FABP6NOS3NOS2NOS1ABL1
SCHEMBL17959867 0.75 TYMS (0.40) TYMSCYP1A2
SCHEMBL12309256 0.74 KDM4E (0.41) ABL1RETKDRCDK7CDK5
SCHEMBL12670573 0.74 GAA (0.42) ABL1RETKDRCDK7CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022140456-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS MEKANISTIC THERAPEUTICS LLC (US) 2022-06-30 WO disclosed
US-9657006-B2 Macrocyclic factor VIIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-23 US disclosed
US-20160115159-A1 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-04-28 US disclosed
US-9174974-B2 Macrocyclic factor VIIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-03 US disclosed
WO-2014201073-A9 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-10-08 WO disclosed
US-20150148313-A1 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-05-28 US disclosed
WO-2014201073-A1 MACROCYCLIC FACTOR VIIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-18 WO disclosed
US-8637542-B2 Kinase inhibitors and methods of use INTELLIKINE, INC. (US) 2014-01-28 US disclosed
WO-2007076431-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148313-A1 MACROCYCLIC FACTOR VIIA INHIBITORS F7, F12, F5 FABP6 594/4885NOS3 3358/4885NOS2 2850/4885
US-20160115159-A1 MACROCYCLIC FACTOR VIIA INHIBITORS F7, F12, F5 FABP6 652/4885NOS3 3573/4885NOS2 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.